Thr1653

Site Information
TRLEGEVtPNsLSTs SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 10852202

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 )
Disease tissue studied:	breast cancer ( 4 ) , breast ductal carcinoma ( 4 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 ) , melanoma skin cancer ( 2 )
Relevant cell line - cell type - tissue:	breast ( 1 , 4 ) , HeLa (cervical) ( 3 , 5 , 15 ) , HepG2 (hepatic) ( 7 , 8 ) , Jurkat (T lymphocyte) ( 14 ) , K562 (erythroid) ( 5 ) , NCI-H2228 (pulmonary) ( 10 , 11 , 12 , 13 ) , NCI-H3255 (pulmonary) ( 6 , 9 ) , WM239A (melanocyte) ( 2 )

Upstream Regulation
Treatments:	ischemia ( 4 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
3	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
4	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
5	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
6	Possemato A (2009) CST Curation Set: 7406; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Curated Info
7	Possemato A (2009) CST Curation Set: 7401; Year: 2009; Biosample/Treatment: cell line, HepG2/untreated; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Curated Info
8	Possemato A (2009) CST Curation Set: 7402; Year: 2009; Biosample/Treatment: cell line, HepG2/untreated; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Curated Info
9	Possemato A (2009) CST Curation Set: 7405; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Curated Info
10	Possemato A (2009) CST Curation Set: 7403; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Curated Info
11	Possemato A (2009) CST Curation Set: 7404; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Curated Info
12	Possemato A (2009) CST Curation Set: 7315; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Curated Info
13	Possemato A (2009) CST Curation Set: 7314; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Curated Info
14	Possemato A (2009) CST Curation Set: 6744; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Curated Info
15	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info